Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF): A Phase IIB Randomized Placebo-Controlled Trial

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by City of Hope Medical Center
Sponsor:
Collaborator:
Information provided by (Responsible Party):
City of Hope Medical Center
ClinicalTrials.gov Identifier:
NCT01347970
First received: May 2, 2011
Last updated: August 6, 2014
Last verified: August 2014

May 2, 2011
August 6, 2014
May 2012
May 2017   (final data collection date for primary outcome measure)
LV thickness-dimension ration (LV T-D), reported in terms of LV posterior wall dimension in systole and LV dimension based on the internal diameter in diastole [ Time Frame: Up to 24 months ] [ Designated as safety issue: No ]
Z-scores appropriately transformed to normality as necessary. The analysis will be conducted using the linear mixed-effects model approach for normally distributed data, to account for correlation among repeated measurements within individuals. This may be done using the generalized estimating equation (GEE) approach without the random effects or by the restricted maximum likelihood estimation (REML) approach with random effects. Various covariance structures will be assumed, including the unstructured, compound symmetry, and autoregressive lag-1 correlation. Implemented using GENMOD & MIXED.
  • Echocardiographic indices of myocardial remodeling and congestive heart failure (CHF) risk [ Time Frame: Every 6 months until day 730 ] [ Designated as safety issue: No ]
    LV T-D, end-systolic wall stress (ESWS), myocardial performance index (MPI), LV internal dimension in diastole (LVEDD), LV isovolumic relaxation time (IVRT), E/A ratio, LV change in systolic diameter (LVESD), wall motion score index (WMSI)
  • Blood biomarkers of myocardial remodeling and CHF risk [ Time Frame: At baseline and every 6 months until day 730 ] [ Designated as safety issue: No ]
    Cardiac Troponins (cTn), Blood Natriuretic peptide (BNP), Galectin-3
  • Safety and tolerability as measured by grade 2-4 toxicities, electrocardiogram and patient reported symptom logs [ Time Frame: At baseline and periodically until day 730 ] [ Designated as safety issue: Yes ]
    Complete blood count, liver panel, electrocardiogram, symptom logs
Complete list of historical versions of study NCT01347970 on ClinicalTrials.gov Archive Site
  • Echocardiographic efficacy measures, including afterload and systolic and diastolic measurements [ Time Frame: Up to 24 months ] [ Designated as safety issue: No ]
    Evaluated in the manner described for primary outcome based on testing the significance of the interaction of time by group indicator variables. The distribution of continuous variables will be examined graphically and appropriate transformations made before applying analytical methods based on normal assumption.
  • Blood biomarkers of myocardial remodeling and CHF risk, including cardiac troponins (cTn), blood natriuretic peptide (BNP), and galectin-3 [ Time Frame: Up to 24 months ] [ Designated as safety issue: No ]
    Treated as continuous measures. The linear mixed effects model for between group comparisons of measures from the 5 time points will be applied. The unstructured mean model and linear in time model will be employed.
  • Grade 2-4 toxicities, assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [ Time Frame: Up to 24 months ] [ Designated as safety issue: Yes ]
    The number of grade 2-4 toxicities observed will be tabulated by treatment arm. Differences by treatment arm will be evaluated using Fisher exact tests.
  • Frequency of individuals with elevated liver function measurements (bilirubin, AST, ALT) [ Time Frame: Up to 24 months ] [ Designated as safety issue: No ]
    Compared between treatment groups using an exact test on 2 x 2 tables, stratified on CYP2D6. Logistic regression analysis will also be used to compare the trends in liver function levels between the treatment groups. Procs MIXED and GLIMMIX will be used for longitudinal analysis of normally and non-normally distributed data, respectively. Proc GENMOD will also be used for normally and non-normally distributed data.
  • Subjective safety and tolerability measures, including treatment adherence as measured by pill counts and patient reported symptoms [ Time Frame: Up to 24 months ] [ Designated as safety issue: No ]
    Voluntary withdrawals will be examined at the end of the study by comparing the percent of withdrawals between the treatment groups using a chi-square test or Fisher's exact test. Patient reported symptoms will be scored as a 5-point Likert-type scale in response to questions on how much patients are bothered by certain symptoms. The responses will be treated as normally distributed, as ordinal or dichotomized variable, and the linear mixed effects model or generalized linear mixed effects model will be applied to compare changes between treatment groups.
Not Provided
Not Provided
Not Provided
 
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF): A Phase IIB Randomized Placebo-Controlled Trial
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF): A Phase IIB Randomized Placebo-Controlled Trial

This randomized phase II trial studies the side effects and how well low-dose carvedilol works in preventing congestive heart failure (CHF) in younger cancer survivors exposed to high dose anthracyclines for management of childhood cancer. Carvedilol may help lower the risk of cardiovascular complications

OBJECTIVES:

I. To determine the impact of a two-year course of low-dose carvedilol on surrogate echocardiographic indices of CHF risk, including: left ventricular (LV) posterior wall thickness-dimension ratio (LV T-D); LV systolic and diastolic function, and afterload; natriuretic peptides, troponins, and galactin-3.

II. To establish safety and tolerability of this two-year course of low-dose carvedilol, assessing both objective measures (hepatic function) and patients reported outcomes.

III. To examine the modifying effect of demographic, clinical, and molecular characteristics on the risk: benefit ratio from this two-year carvedilol intervention.

IV. As an exploratory goal, to examine the relationship between carvedilol and clinical measures of efficacy such as prevention of CHF.

OUTLINE: This is a dose-escalation study. Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive low-dose carvedilol orally (PO) once (QD) or twice daily (BID) for 24 months.

ARM II: Patients receive placebo PO QD or BID for 24 months.

After completion of study treatment, patients are followed up annually.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Supportive Care
Cancer Survivor
  • Drug: carvedilol
    Given PO
    Other Name: Coreg
  • Other: placebo
    Given PO
    Other Name: PLCB
  • Other: pharmacogenomic studies
    Correlative studies
    Other Name: Pharmacogenomic Study
  • Other: laboratory biomarker analysis
    Correlative studies
  • Procedure: quality-of-life assessment
    Ancillary studies
    Other Name: quality of life assessment
  • Genetic: polymorphism analysis
    Correlative studies
  • Genetic: microarray analysis
    Correlative studies
    Other Name: gene expression profiling
  • Genetic: polymerase chain reaction
    Correlative studies
    Other Name: PCR
  • Other: enzyme-linked immunosorbent assay
    Correlative studies
    Other Name: ELISA
  • Other: questionnaire administration
    Ancillary studies
  • Experimental: Arm I (beta-adrenergic/alpha-1 adrenergic blocker)
    Patients receive low-dose carvedilol PO QD or BID for 24 months.
    Interventions:
    • Drug: carvedilol
    • Other: pharmacogenomic studies
    • Other: laboratory biomarker analysis
    • Procedure: quality-of-life assessment
    • Genetic: polymorphism analysis
    • Genetic: microarray analysis
    • Genetic: polymerase chain reaction
    • Other: enzyme-linked immunosorbent assay
    • Other: questionnaire administration
  • Placebo Comparator: Arm II (placebo)
    Patients receive placebo PO QD or BID for 24 months.
    Interventions:
    • Other: placebo
    • Other: pharmacogenomic studies
    • Other: laboratory biomarker analysis
    • Procedure: quality-of-life assessment
    • Genetic: polymorphism analysis
    • Genetic: microarray analysis
    • Genetic: polymerase chain reaction
    • Other: enzyme-linked immunosorbent assay
    • Other: questionnaire administration
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
250
Not Provided
May 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Cancer diagnosis prior to 22 years of age, irrespective of current age
  • Lifetime cumulative anthracycline dose: >= 300 mg/m^2 without the protection of dexrazoxane (Zinecard) therapy
  • Time from completion of cancer treatment to study entry: >= 2 years

Exclusion Criteria:

  • Receiving treatment for cardiomyopathy or congestive heart failure
  • Resting ejection fraction < 50% or fractional shortening < 25%
  • Uncorrected primary obstructive or severe regurgitative valvular disease, nondilated (restrictive) or hypertrophic cardiomyopathy, or significant systemic ventricular outflow obstruction
  • Low resting systolic blood pressure: < 90 mm hemoglobin (Hg)
  • Bradycardia: heart rate < 50 beats per minute (BPM)
  • Sustained or symptomatic ventricular dysrhythmias uncontrolled with drug therapy or implantable device; significant conduction defects (i.e.: second or third degree atrio-ventricular block or sick sinus syndrome)
  • History or current clinical evidence of moderate -to-severe obstructive pulmonary disease or reactive airway diseases (i.e.: asthma) requiring therapy
  • Significant hepatic (serum aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT] > 3 time upper limit of normal institutional normal), gastrointestinal, or biliary disorders that could impair absorption, metabolism, or excretion of orally administered medications
  • Endocrine disorders such as primary aldosteronism, pheochromocytoma, hyper- or hypothyroidism not controlled with medication, or insulin dependent diabetes mellitus
  • Females of child bearing potential who are pregnant, lactating, or sexually active and not taking adequate contraceptive precautions (i.e.: intrauterine device [IUD] or oral contraceptives for 3 months prior to entry into the study)
  • History of drug sensitivity or allergic reaction to alpha- or beta-blockers
  • Anemia (hematocrit < 28%)
  • Use of an investigational drug or beta adrenergic blockers, including metoprolol, sotalol, within 30 days of randomization
  • Use of select cytochrome P450 2D6 (CYP2D6) inhibitor medications
  • Inability to swallow pills
  • Unwillingness or inability to cooperate, or, for the parents or guardians of minors, to give consent, or for the child to give assent, or any condition of sufficient severity to impair cooperation with the study
  • Use of any other blood pressure lowering medication for treatment of hypertension, within 30 days of randomization
Both
16 Years and older
No
United States,   Canada
 
NCT01347970
11018, NCI-2011-00717, K12CA001727
Yes
City of Hope Medical Center
City of Hope Medical Center
National Cancer Institute (NCI)
Principal Investigator: Saro Armenian, DO, MPH City of Hope Medical Center
City of Hope Medical Center
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP